|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | CML FAQ | **Project Code** | PB4VFQ093 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey Goins |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**Items highlighted in GREEN are still TBD and will be filled out later**

1. **[Title---always italicized, no bold, no quotes]**

Frequently Asked Questions in Chronic Myeloid Leukemia Resistant to Standard Therapy: Expert Video and Slide Library

1. **[Date – format varies per product]**

**RELEASE DATE**

**X December 2014**

**EXPIRATION DATE**

**X December 2015**

1. **[Activity Overview/Introduction]—Delete what is not needed, complete what is needed**

This video and slide library features answers from key experts to commonly asked questions regarding the optimal management of patients with CML who have disease progression following initial TKI therapy.

***\*\*\*Note: Community Opinion activities are different and do not follow this template.\*\*\****

1. **[Target Audience]**

This educational activity is specifically designed to address the educational needs of practicing hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with CML.

1. **[Learning Objectives]**

After successful completion of this educational activity, participants should be able to:

* Evaluate recent clinical trial data focused on the treatment of patients with chronic myelogenous leukemia (CML) with resistance to tyrosine kinase inhibitors (TKIs)
* Identify optimal strategies for selecting and sequencing therapy for patients with CML with disease progression following initial TKI therapy
* Describe best practices for the identification and management of treatment-related adverse events in patients with relapsed CML to improve tolerability and quality of life

1. **[Faculty Listing---note bolding and lack of colons]**

**Francisco Cervantes, MD, PhD**

Hospital Clinic Barcelona

Barcelona, Spain

**Jorge E. Cortes, MD**

The University of Texas   
MD Anderson Cancer Center

Houston, Texas, United States

**Elias Jabbour, MD**  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas, United States

**Giuseppe Saglio, MD**

University of Turin

Turin, Italy

**Neil Shah, MD, PhD**

University of Californina, San Francisco

San Francisco, California

1. **[Topics/Abstracts]**

**[-/+] Introduction**

Introduction from the course director *(Jabbour intro)*

**[-/+] Selecting Therapy for Resistant CML**

How do you determine when a patient has become resistant to their current therapy? *(Cervantes video 1)*

Should patients with resistance to second generation TKI therapy be switched to another second generation TKI or move to a third generation TKI? *(Jabbour video 1)*

What is the best therapy choice for patients with *T315I* mutations? *(Saglio video 1)*

Is there a role for stem cell transplant in patients with resistant CML? *(Shah Video)*

What TKI should you offer to a patient with advanced disease (advanced phase or blast phase)? *(Cortes)*

**[-/+] Quality of Life in Resistant CML**

How do you assess the risks and benefits of a TKI for patients with resistant disease and what dictates your choice of therapy? *(Shah Video)*

Is it safe for patients with adverse reactions to second generation TKIs to receive third generation TKIs? *(Cervantes video 2)*

How do I manage dosing of third generation TKI therapy? *(Jabbour video 2)*

What is the safety profile of third generation TKIs and how to I manage these adverse events? *(Salio video 2)*

Are there any steps that I can take to mitigate the risk of adverse events in patients receiving third generation TKIs? *(Cortes Video To Be Filmed)*

1. **[Provider Statement]**

This activity is provided by prIME Oncology.



**9. [Support Statement—consult Cindy for proper verbiage]- NO LOGO**

This educational activity is supported by a grant from ARIAD Pharmaceuticals, Inc.

**10. [Continuing Education---choose one]**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this enduring activity for a maximum of *XX AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

\*\*All CME/CE verbiage should receive final approval from Regulatory/Compliance Manager

**Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx) [[link to our Terms page]]

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 80% or higher.

**11. [Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Cervantes disclosed that he has received consulting fees from Ariad, Novartis, and Pfizer. He has also received fees for non-CME services from Bristo- Myers Squibb and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cortes has disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. He has also performed contracted research for Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jabbour disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Saglio disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

DrShah has disclosed that he has received contracted research for Ariad and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical content reviewer/planner) - no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) - no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**12. [URL and Mobile App Name---give suggestions for URL name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

Insert URL here.

www.primeoncology.org/2014CMLFAQ

\*\*Note: Do not include the name of the congress or society in the URL.

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **2014 CML FAQ**

Meta Description

Key Words/Key Phrases

**13. [Subject Line for Email Blast]**

*Frequently Asked Questions About CML: New Video and Slides*

**14. [Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Providership (with logos)

Support (with no logos)

**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | CML FAQ | **Project Code** | PB4VFQ093 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey Goins |
| **Compliance** | Briana Devaser | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**Before EOY**

**Project Type**

Webcast

Downloadable Slides

Podcast

Other: **FAQ Video Library**

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides (as download button only)**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: 2014 CML FAQ**